Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma
Phase 3 Trial to Determine the Efficacy of Topical Hypericin combined with Fluorescent Light Therapy on Cutaneous T-Cell Lymphoma
Sponsor: Soligenix
Enrolling: Male and Female Patients
Study Length: 1 Years
IRB Number: AAAR3953
U.S. Govt. ID: NCT02448381
Contact: Grace Ulerio: 212-305-6953 /
Additional Study Information: This is a phase 3 clinical trial to determine the efficacy of topical SGX301 (synthetic hypericin) in combination with visible light therapy on cutaneous T-cell lymphoma (CTCL). Selected subjects can participate in 3 cycles each consisting of a 6 week treatment period where a chosen lesion will be treated with the study ointment (twice a week) followed by light therapy the next day. All subjects will be seen monthly after their last treatment for 6 month to assess for any lesional changes. The study will include 2 skin biopsies and blood collections which will be used to measure the safety and efficacy of the drug. The study duration is approximately 1 year.
This study is closed
Larisa Geskin, MD
Do You Qualify?
Do you have CTCL in Stage 1A, Stage 1B, or Stage IIA? Yes No
Do you have a minimum of three discrete lesions? Yes No
Can you adhere to the study duration of approximately 1 year? Yes No
(Female only) Are you pregnant or nursing? (If male, mark 'NO') Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Grace Ulerio